Literature DB >> 16033955

hOCT 1 and resistance to imatinib.

Lucy C Crossman, Brian J Druker, Michael W N Deininger, Munir Pirmohamed, Lihui Wang, Richard E Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16033955     DOI： 10.1182/blood-2005-02-0694

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  51 in total

1.  Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.

Authors:  Qiu-bai Li; Chao Chen; Zhi-chao Chen; Hong-xiang Wang; Yan-lin Wu; Yong You; Ping Zou
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

Review 2.  Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Authors:  Margaret von Mehren; Nicolas Widmer
Journal:  Cancer Treat Rev       Date:  2010-11-24       Impact factor: 12.111

3.  Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Authors:  N Widmer; L A Decosterd; C Csajka; S Leyvraz; M A Duchosal; A Rosselet; B Rochat; C B Eap; H Henry; J Biollaz; T Buclin
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

4.  Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Authors:  François Guilhot; Timothy P Hughes; Jorge Cortes; Brian J Druker; Michele Baccarani; Insa Gathmann; Michael Hayes; Camille Granvil; Yanfeng Wang
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 6.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

7.  The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors:  L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

8.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

Authors:  Luciene Terezina de Lima; Douglas Vivona; Carolina Tosin Bueno; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Fabíola Attié de Castro; Maria de Lourdes F Chauffaille; Maria A Zanichelli; Carlos S Chiattone; Vania T M Hungria; Elvira M Guerra-Shinohara
Journal:  Med Oncol       Date:  2014-01-29       Impact factor: 3.064

9.  A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Authors:  Shannon K McWeeney; Lucy C Pemberton; Marc M Loriaux; Kristina Vartanian; Stephanie G Willis; Gregory Yochum; Beth Wilmot; Yaron Turpaz; Raji Pillai; Brian J Druker; Jennifer L Snead; Mary MacPartlin; Stephen G O'Brien; Junia V Melo; Thoralf Lange; Christina A Harrington; Michael W N Deininger
Journal:  Blood       Date:  2009-10-16       Impact factor: 22.113

10.  Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.

Authors:  N Singh; L Kumar; R Meena; T Velpandian
Journal:  Eur J Clin Pharmacol       Date:  2009-02-12       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.